サリルマブ
“Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal”. PharmacoEconomics 36 (12): 1427–1437. (June 2018). doi:10.1007/s40273-018-0677-7. PMID 29882210. http://eprints.whiterose.ac.uk/131862/3/Pharmacoeconomics%20sarilumab%20v4.pdf.
“Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes”. Rheumatology (Oxford, England) 57 (8): 1423–1431. (August 2018). doi:10.1093/rheumatology/key121. PMC 6055572.